EP1515971A2 - Derives de nucleosides carbocycliques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale - Google Patents

Derives de nucleosides carbocycliques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale

Info

Publication number
EP1515971A2
EP1515971A2 EP03760371A EP03760371A EP1515971A2 EP 1515971 A2 EP1515971 A2 EP 1515971A2 EP 03760371 A EP03760371 A EP 03760371A EP 03760371 A EP03760371 A EP 03760371A EP 1515971 A2 EP1515971 A2 EP 1515971A2
Authority
EP
European Patent Office
Prior art keywords
amino
hydrogen
alkyl
hydroxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03760371A
Other languages
German (de)
English (en)
Inventor
Balkrishen Bhat
Neelima Bhat
Prasad Dande
Anne B. Eldrup
David B. Olsen
Malcolm Maccoss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Ionis Pharmaceuticals Inc
Original Assignee
Merck and Co Inc
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc, Isis Pharmaceuticals Inc filed Critical Merck and Co Inc
Publication of EP1515971A2 publication Critical patent/EP1515971A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de nucléosides carbocycliques et certains de leurs dérivés qui sont des inhibiteurs de l'ARN polymérase ARN-dépendante virale. Ces composés sont des inhibiteurs de la réplication virale de l'ARN ARN-dépendante et sont utiles pour le traitement d'une infection virale ARN ARN-dépendante. Ces composés sont tout particulièrement utiles comme inhibiteurs de la polymérase NS5B du virus de l'hépatite C (VHC), comme inhibiteurs de la réplication du VHC, et/ou pour le traitement d'une infection par le virus de l'hépatite C. L'invention concerne également des compositions pharmaceutiques contenant ces composés de nucléosides carbocycliques seuls ou combinés à d'autres agents actifs contre une infection virale ARN ARN-dépendante, en particulier une infection par le virus de l'hépatite C. L'invention concerne également des méthodes permettant d'inhiber l'ARN polymérase ARN-dépendante, d'inhiber la réplication virale de l'ARN ARN-dépendante, et/ou de traiter une infection virale ARN ARN-dépendante, utilisant les composés de nucléosides carbocycliques de la présente invention.
EP03760371A 2002-06-17 2003-06-14 Derives de nucleosides carbocycliques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale Withdrawn EP1515971A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38916102P 2002-06-17 2002-06-17
US389161P 2002-06-17
PCT/US2003/018841 WO2003105770A2 (fr) 2002-06-17 2003-06-14 Derives de nucleosides carbocycliques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale

Publications (1)

Publication Number Publication Date
EP1515971A2 true EP1515971A2 (fr) 2005-03-23

Family

ID=29736594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03760371A Withdrawn EP1515971A2 (fr) 2002-06-17 2003-06-14 Derives de nucleosides carbocycliques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale

Country Status (5)

Country Link
EP (1) EP1515971A2 (fr)
JP (1) JP2005533777A (fr)
AU (1) AU2003251524A1 (fr)
CA (1) CA2488842A1 (fr)
WO (1) WO2003105770A2 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
OA12382A (en) 2000-05-26 2006-04-17 Novirio Pharmaceuticals Ltd Methods and compositions for treating flavivirusesand pestiviruses.
RS114004A (en) * 2002-06-28 2007-02-05 Idenix (Cayman) Limited, Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
US7323449B2 (en) 2002-07-24 2008-01-29 Merck & Co., Inc. Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
BRPI0410846B8 (pt) 2003-05-30 2021-05-25 Gilead Pharmasset Llc nucleosídeo e composição farmacêutica compreendendo o mesmo
TWI368507B (en) 2004-02-20 2012-07-21 Boehringer Ingelheim Int Viral polymerase inhibitors
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
RU2433124C2 (ru) 2004-09-14 2011-11-10 Фармассет, Инк. Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
BRPI0515896A (pt) * 2004-09-24 2008-08-12 Idenix Cayman Ltd E Ct Nat De composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
CN101460488A (zh) 2006-04-04 2009-06-17 弗·哈夫曼-拉罗切有限公司 用于hcv治疗的3’,5’-二-o-酰化核苷
KR101165936B1 (ko) 2006-11-09 2012-07-19 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2655028T3 (es) 2007-08-02 2018-02-16 Millennium Pharmaceuticals, Inc. Proceso para la síntesis de inhibidores de enzima de activación de E1
EP2234981B1 (fr) 2007-12-17 2016-03-30 F. Hoffmann-La Roche AG Nouvelles arylamides substituées imidazole
CA2708228C (fr) 2007-12-17 2016-06-21 F. Hoffmann-La Roche Ag Derives d'arylamides a substitution tetrazole et leur utilisation comme antagonistes du recepteur purinergique p2x3 ou p2x2/3
MX2010006230A (es) 2007-12-17 2010-06-23 Hoffmann La Roche Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
DK2234976T3 (da) 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
EP2326627A1 (fr) * 2008-08-20 2011-06-01 Schering Corporation Dérivés de pyridine et pyrimidine substituées et leur utilisation dans le traitement d'infections virales
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010075549A2 (fr) 2008-12-23 2010-07-01 Pharmasset, Inc. Phosphoramidates de nucléosides
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2445897B1 (fr) 2009-06-22 2014-03-19 F.Hoffmann-La Roche Ag Nouveaux arylamides d'indazole comme antagonistes de p2x3 et/ou p2x2/3
ES2450891T3 (es) 2009-06-22 2014-03-25 F. Hoffmann-La Roche Ag Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3
JP5465782B2 (ja) 2009-06-22 2014-04-09 エフ．ホフマン−ラ ロシュ アーゲー 新規オキサゾロン及びピロリジノン置換アリールアミド
CN102713630A (zh) 2009-11-14 2012-10-03 弗·哈夫曼-拉罗切有限公司 用于预测对hcv治疗的快速应答的生物标志物
CN102656459A (zh) 2009-12-02 2012-09-05 弗·哈夫曼-拉罗切有限公司 用于预测对hcv治疗持续应答的生物标志物
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
MX2012011222A (es) 2010-04-01 2013-01-18 Centre Nat Rech Scient Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
CA2818853A1 (fr) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides destines a la therapie contre le virus de l'hepatite c et le virus de la dengue
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Pharmasset Llc Methods for treating HCV
WO2013056046A1 (fr) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Phosphates 3',5'-cycliques substitués de composés nucléotidiques purines et compositions pharmaceutiques pour le traitement d'infections virales
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
WO2013177188A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
WO2013177195A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
CN104395330B (zh) 2012-05-25 2018-03-13 爱尔兰詹森科学公司 尿嘧啶基螺氧杂环丁烷核苷
WO2014052638A1 (fr) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters et malonates de promédicaments à base de s-acyl-2-thioéthyle (sate)
US10513534B2 (en) 2012-10-08 2019-12-24 Idenix Pharmaceuticals Llc 2′-chloro nucleoside analogs for HCV infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014099941A1 (fr) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
WO2014137930A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Nucléosides de thiophosphate pour le traitement du vhc
EP2970358B1 (fr) 2013-03-04 2021-06-30 Idenix Pharmaceuticals LLC 3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
EP2970357A1 (fr) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Pronucléotides de phosphoramidate d'acide aminé de 2'-cyano, azido et amino nucléosides pour le traitement du virus de l'hépatite c (vhc)
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
WO2014165542A1 (fr) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoronucléosides pour le traitement du vhc
CN110156838A (zh) * 2013-05-14 2019-08-23 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
EP3004130B1 (fr) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
EP3027636B1 (fr) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC Phosphoramidate de d-acides aminés pronucleotidiques dérivés de pyrimidine halogenée pour des maladies du foie
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
CN103524423B (zh) * 2013-09-18 2015-11-04 苏州乔纳森新材料科技有限公司 4,6-二氯代嘧啶-5-乙醛的制备方法
CN103554035B (zh) * 2013-10-29 2015-07-15 苏州乔纳森新材料科技有限公司 4,6-二卤代嘧啶-5-乙醛的制备方法
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
WO2016134054A1 (fr) * 2015-02-18 2016-08-25 Abbvie Inc. Composés anti-viraux
WO2016134056A1 (fr) * 2015-02-18 2016-08-25 Abbvie Inc. Composés anti-viraux
WO2016134051A1 (fr) * 2015-02-18 2016-08-25 Abbvie Inc. Composés anti-viraux
WO2016134057A1 (fr) * 2015-02-18 2016-08-25 Abbvie Inc. Composés anti-viraux
WO2017040766A1 (fr) 2015-09-02 2017-03-09 Abbvie Inc. Dérivés anti-viraux de tétrahydrofurane
CN109956975B (zh) * 2017-12-22 2020-11-06 浙江柏拉阿图医药科技有限公司 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用
CN109761984B (zh) * 2019-02-27 2020-07-07 河南师范大学 不对称氢转移合成手性五元碳环嘌呤核苷的方法
CN112274516B (zh) * 2020-10-26 2022-08-05 中山大学附属第三医院 一种新型含碘抗病毒药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215970A (en) * 1987-04-16 1993-06-01 Medivir Ab Nucleosides and nucleotide analogues, pharmaceutical composition and processes for the preparation of the compounds
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5723466A (en) * 1991-12-06 1998-03-03 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03105770A2 *

Also Published As

Publication number Publication date
AU2003251524A1 (en) 2003-12-31
WO2003105770A3 (fr) 2004-10-07
JP2005533777A (ja) 2005-11-10
WO2003105770A2 (fr) 2003-12-24
CA2488842A1 (fr) 2003-12-24

Similar Documents

Publication Publication Date Title
EP1515971A2 (fr) Derives de nucleosides carbocycliques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale
EP1355916B1 (fr) Derives de nucleoside servant d'inhibiteurs de l'arn polymerase virale arn dependante
US7323449B2 (en) Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US20080280842A1 (en) Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
US20060264389A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20070004669A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20040229840A1 (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US20040110717A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20060234962A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20170183373A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polyermase
AU2002243791A1 (en) Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1773355A2 (fr) Phosphoramidates d'aryle nucleosidiques pour le traitement d'infection virale arn dependante de l'arn
WO2003020222A2 (fr) Derives de dioxolane et d'oxathiolane en tant qu'inhibiteurs de l'arn polymerase virale dependante de l'arn

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20050407

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

Owner name: MERCK & CO., INC.

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20050407

Extension state: LT

Payment date: 20050407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20081024